Tracking 39+ Companies & 53+ Open Roles

The career platform for psychedelic medicine

Company intelligence, jobs, clinical trials, and practitioner resources — everything you need to build a career in the emerging psychedelic industry.

39+
Companies tracked
53+
Open positions
22
Active clinical trials
17
States with legislation
COMPASS PathwaysCOMP360 · Treatment-Resistant DepressionPhase 3·
Helus PharmaCYB003 · Major Depressive DisorderPhase 3·
Definium TherapeuticsMM120 · Generalized AnxietyPhase 3·
GH ResearchGH001 · Treatment-Resistant DepressionPhase 2b·
AtaiBeckleyBPL-003 · Treatment-Resistant DepressionPhase 2b·
EnvericEB-003 · PTSDPreclinical·
COMPASS PathwaysCOMP360 · Treatment-Resistant DepressionPhase 3·
Helus PharmaCYB003 · Major Depressive DisorderPhase 3·
Definium TherapeuticsMM120 · Generalized AnxietyPhase 3·
GH ResearchGH001 · Treatment-Resistant DepressionPhase 2b·
AtaiBeckleyBPL-003 · Treatment-Resistant DepressionPhase 2b·
EnvericEB-003 · PTSDPreclinical·
Companies

The psychedelic medicine ecosystem

View All 39+ Companies →
NB

Neurocrine Biosciences

NBIX
$13.9B
Mkt Cap
—
Raised
0
Open Roles
SP

Supernus Pharmaceuticals

SUPN
$2.8B
Mkt Cap
—
Raised
0
Open Roles
CP

COMPASS Pathways

CMPS
Phase 3psilocybinHiring
$850M
Mkt Cap
—
Raised
34
Open Roles
BM

Bright Minds Biosciences

DRUG
$740M
Mkt Cap
—
Raised
0
Open Roles
A

AtaiBeckley

ATAI
$600M
Mkt Cap
—
Raised
0
Open Roles
LT

Lykos Therapeutics

Phase 3MDMA
—
Mkt Cap
—
Raised
0
Open Roles

Stay ahead of the industry

Get weekly updates on new job listings, clinical trial progress, and regulatory changes across all 50 states.